Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 4 2000
Play
Audio Below:
I
spent a week one afternoon trying to go over that with our reproductive
gynecologist and actually went back and forth over two or three
weeks trying to understand what was going on with venlafaxine and
serotonin and epinephrine in the pituitary and the hypothalamus,
and it is very complicated. And there is blood-brain-barrier in
one area and not the other area. And with these rat studies they
do these micropipets of vascular structures in these areas. It’s
very confusing and not well understood. But it has to be something
with the loss of hormones, either estrogen in women or androgen
in men, more problem with acute loss of this – i.e. an orchiectomy
or an oophorectomy, seems to bring on these things faster and some
how with some just regulation in the temperature-setting mechanism,
probably in the pituitary or hypothalamus area of the central nervous
system. But other than that more detail is very difficult to figure
out. We hope that we might get a better feel for that with looking
to the newer anti-depressants, because they have a variety of different
effects. There is a variety of these anti-depressants which appear
to work, only one of which has been proven in a randomized placebo
control trial – proven in my eye, in terms of our stuff, which
hasn’t been published yet. So I can understand that the community
out there does not have the actual information to look at, which
is a shame. And we are working hard on getting that out.
Biopsy
confirmed benign breast disease, postmenopausal use of exogenous
female hormones, and breast carcinoma risk. Byrne,
C.; Connolly, J. L.; Colditz, G. A., and Schnitt, S. J.. Cancer.
89(10):2046-2052, 2000 Nov 15.
Postmenopausal
estrogens - Opposed, unopposed, or none of the above Willett, W. C.; Colditz, G., and Stampfer, M. (Reprint available
from: Willett WC Harvard Univ, Sch Publ Hlth, Dept Nutr 667 Huntington
Ave Boston, MA 02115 USA).. Jama: Journal of the American Medical
Association. 283(4):534-535, 2000 Jan 26. No abstract
Re:
Effect of hormone replacement therapy on breast cancer risk: Estrogen
versus estrogen plus progestin Archer, D. F.; Bush, T., and Nachtigall, L. E. (Reprint available
from: Nachtigall LE NYU, Sch Med, Dept Obstet & Gynecol 251
E 33rd St New York, NY 10016 USA).. Journal of the National Cancer
Institute. 92(23):1950-1951, 2000 Dec 6. No abstract
Estrogen
deficiency: In search of symptom control and sexuality. Loprinzi,
C. L. and Barton, D. Journal of the National Cancer Institute. 92(13):1028-1029,
2000 Jul 5. No abstract
